Why You Should Consider Buying ResMed Stock After Its First-Ever Annual Guide
ResMed (RMD) issued its first full annual guidance for FY27, targeting $5.75B to $5.85B revenue and non-GAAP EPS of $12.00 to $12.25, with 5% to 7% core constant-currency revenue growth and 12% to 14% core EPS growth after an Astral ventilator sales suspension. Q4 results included $1.5B revenue and $2.95 non-GAAP EPS. Analysts’ mean target is $247.20 vs. $224.46 close.
How this was made
The 30-second read
Why it matters
ResMed disclosed FY27 revenue and non-GAAP EPS guidance and quantified how Astral suspension, MatrixCare divestiture dilution, and Noctrix acquisition dilution affect the reported numbers versus core growth.
Market read
Traders can reassess valuation and expectations using the disclosed FY27 ranges and the stated bridge to core EPS growth, while monitoring whether analyst target cuts reflect skepticism about the headwind roll-off.
What to watch
Execution risk around the Astral field safety action timing, the MatrixCare divestiture closing/dilution profile, and Noctrix acquisition integration could keep reported EPS below the core narrative.
Background
The article frames ResMed’s first annual guidance since going public, contrasting headline growth with “core” growth after excluding specific headwinds.
Ticker impact
ResMed’s first-ever full annual guidance for FY27 targets $5.75B to $5.85B revenue and non-GAAP EPS $12.00 to $12.25, with core EPS growth 12% to 14% after Astral and other headwinds roll off.
Near-term trading likely hinges on whether investors believe the Astral suspension and divestiture/dilution effects are temporary versus structural; upside bias if core growth credibility improves, downside if headline EPS remains pressured.
The article provides specific FY27 revenue and EPS ranges plus a bridge to core EPS growth, but it is framed as a promotional analysis and does not add new post-guidance market reaction beyond the stated target-trend context.
Market effects
Could influence sentiment across sleep-disordered breathing device peers by highlighting how safety actions and product suspensions can be separated from underlying core growth.
No explicit regional read-through beyond ResMed’s Americas and rest-of-world sleep device revenue growth rates.
Limited, as the piece is company-specific and does not cite broader regulatory or industry-wide actions.
Counterpoint
The guidance’s headline EPS range implies only modest growth, and the article’s core-growth bridge depends on headwinds rolling off on schedule, which may not be fully controllable.
Key entities
- companyResMed
Guidance issuer for FY27 revenue and non-GAAP EPS, with core growth adjusted for Astral suspension and other items.
- productAstral ventilator
Sales are suspended during an ongoing field safety action, creating a stated top-line headwind.
- corporate_actionMatrixCare divestiture
Pending divestiture cited as contributing dilution to headline EPS comparisons.
- corporate_actionNoctrix acquisition
Cited as contributing dilution to headline EPS comparisons.
